Phase 1 and phase 2 drug metabolism and bile acid production of HepaRG cells in a bioartificial liver in absence of dimethyl sulfoxide

Drug Metabolism and Disposition

Volumn 41, Issue 3, 2013, Pages 562-567

  Hoekstra, Ruurdtje ^a   Nibourg, Geert A A ^a   Van Der Hoeven, Tessa V ^a   Plomer, Gabrielle ^a   Seppen, Jurgen ^a   Ackermans, Mariëtte T ^b   Camus, Sandrine ^a,d   Kulik, Wim ^c   Van Gulik, Thomas M ^a   Oude Elferink, Ronald P ^a   Chamuleau, Robert A F M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Laboratory of Endocrinology   (Netherlands)

^c Laboratory of Endocrinology ^*  (Netherlands)

^d Biopredic International   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE SALT; BILIRUBIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIMETHYL SULFOXIDE; GLUCURONOSYLTRANSFERASE 1A1; RIFAMPICIN; TESTOSTERONE; TOLBUTAMIDE;

ADULT; ARTICLE; BILE ACID SYNTHESIS; BIOARTIFICIAL LIVER; CONJUGATION; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER CELL; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BILE ACIDS AND SALTS; BILIRUBIN; BIOREACTORS; BIOTRANSFORMATION; CELL CULTURE TECHNIQUES; CELL LINE; CYTOCHROME P-450 CYP3A; DIMETHYL SULFOXIDE; GLUCURONOSYLTRANSFERASE; HEPATOCYTES; HUMANS; HYDROXYLATION; ISOENZYMES; KINETICS; LIVER, ARTIFICIAL; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; RIFAMPIN; SUBSTRATE SPECIFICITY; TESTOSTERONE; TOLBUTAMIDE;

EID: 84874066942     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.049098     Document Type: Article

References (32)

1. Andersson TB, Kanebratt KP, and Kenna JG (2012) The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Expert Opin Drug Metab Toxicol 8:909-920.
2. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83.
3. Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, and Guguen-Guillouzo C, et al. (2010) Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab Dispos 38:516-525.
4. Bohan A and Boyer JL (2002) Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis 22:123-136.
5. Bootsma AH, Overmars H, van Rooij A, van Lint AE, Wanders RJ, van Gennip AH, and Vreken P (1999) Rapid analysis of conjugated bile acids in plasma using electrospray tandem mass spectrometry: application for selective screening of peroxisomal disorders. J Inherit Metab Dis 22:307-310.
6. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, and Corlu A (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45:957-967.
7. Darnell M, Schreiter T, Zeilinger K, Urbaniak T, Söderdahl T, Rossberg I, Dillnér B, Berg AL, Gerlach JC, and Andersson TB (2011) Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab Dispos 39:1131-1138.
8. Darnell MH, Ulvestad M, Ellis E, Weidolf L, and Andersson TB (2012) In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system. J Pharmacol Exp Ther 343: 134-144.
9. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, and Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273:10046-10050.
10. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, and Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655-15660.
11. Hoekstra R, Deurholt T, ten Bloemendaal L, Desille M, van Wijk AC, Clement B, Oude Elferink RP, van Gulik TM, and Chamuleaut RA (2006) Assessment of in vitro applicability of reversibly immortalized NKNT-3 cells and clonal derivatives. Cell Transplant 15: 423-433.
12. Hoekstra R, Nibourg GAA, van der Hoeven TV, Ackermans MT, Hakvoort TB, van Gulik TM, Lamers WH, Elferink RP, and Chamuleau RA (2011) The HepaRG cell line is suitable for bioartificial liver application. Int J Biochem Cell Biol 43:1483-1489.
13. Jennen DG, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MH, Kleinjans JC, and van Delft JH (2010) Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 115:66-79.
14. Kanebratt KP and Andersson TB (2008) HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:137-145.
15. Kosters A and Karpen SJ (2008) Bile acid transporters in health and disease. Xenobiotica 38: 1043-1071.
16. Lambert CB, Spire C, Claude N, and Guillouzo A (2009) Dose-and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234:345-360.
17. Landry J, Bernier D, Ouellet C, Goyette R, and Marceau N (1985) Spheroidal aggregate culture of rat liver cells: histotypic reorganization, biomatrix deposition, and maintenance of functional activities. J Cell Biol 101:914-923.
18. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, and Fardel O (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109-117.
19. Legendre C, Hori T, Loyer P, Aninat C, Ishida S, Glaise D, Lucas-Clerc C, Boudjema K, Guguen-Guillouzo C, and Corlu A, et al. (2009) Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer 45:2882-2892.
20. McGill MR, Yan HM, Ramachandran A, Murray GJ, Rollins DE, and Jaeschke H (2011) HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 53:974-982.
21. Nibourg GA, Chamuleau RA, van der Hoeven TV, Maas MA, Ruiter AF, Lamers WH, Oude Elferink RP, van Gulik TM, and Hoekstra R (2012) Liver progenitor cell line HepaRG differentiated in a bioartificial liver effectively supplies liver support to rats with acute liver failure. PLoS ONE 7:e38778.
22. Nibourg GAA, Huisman MTH, van der Hoeven TV, van Gulik TM, Chamuleau RAFM, and Hoekstra R (2010) Stable overexpression of pregnane X receptor in HepG2 cells increases its potential for bioartificial liver application. Liver Transpl 16:1075-1085.
23. Paulusma CC, Kothe MJ, Bakker CT, Bosma PJ, van Bokhoven I, van Marle J, Bolder U, Tytgat GN, and Oude Elferink RP (2000) Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 31:684-693.
24. Poyck PP, Hoekstra R, Chhatta A, Bloemendaal LT, van Wijk AC, Galavotti D, van Gulik TM, and Chamuleau RA (2007) Time-related analysis of metabolic liver functions, cellular morphology, and gene expression of hepatocytes cultured in the bioartificial liver of the Academic Medical Center in Amsterdam (AMC-BAL). Tissue Eng 13:1235-1246.
25. Poyck PP, Mareels G, Hoekstra R, van Wijk AC, van der Hoeven TV, van Gulik TM, Verdonck PR, and Chamuleau RA (2008) Enhanced oxygen availability improves liver-specific functions of the AMC bioartificial liver. Artif Organs 32:116-126.
26. Seppen J, Bakker C, de Jong B, Kunne C, van den Oever K, Vandenberghe K, de Waart R, Twisk J, and Bosma P (2006) Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther 13:1085-1092.
27. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, Jansen PL, and Oude Elferink RP (1994) Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate- glucuronosyltransferase. J Clin Invest 94: 2385-2391.
28. Stirnimann G, Kessebohm K, and Lauterburg B (2010) Liver injury caused by drugs: an update. Swiss Med Wkly 140:w13080.
29. Tilles AW, Baskaran H, Roy P, Yarmush ML, and Toner M (2001) Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotechnol Bioeng 73:379-389.
30. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, and Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4alpha determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
31. Trottier J, Milkiewicz P, Kaeding J, Verreault M, and Barbier O (2006) Coordinate regulation of hepatic bile acid oxidation and conjugation by nuclear receptors. Mol Pharm 3:212-222.
32. van de Kerkhove MP, Poyck PP, van Wijk AC, Galavotti D, Hoekstra R, van Gulik TM, and Chamuleau RA (2005) Assessment and improvement of liver specific function of the AMC-bioartificial liver. Int J Artif Organs 28:617-630.